Progression of Time-Dependent Changes to the Mechanisms of Vasodilation by Protease-Activated Receptor 2 in Metabolic Syndrome

• Published in: Biological & pharmaceutical bulletin 2017/12/01, Vol.40(12), pp.2039-2044
• Main Authors: Maruyama, Kana, McGuire, John J., Kagota, Satomi
• Format: Article
• Language: English
• Subjects: Adipocytes; Age; Age Factors; Animal models; Animals; Cardiovascular system; Cardiovascular System - pathology; Chronic exposure; Cytokines; Disease Models, Animal; Disease Progression; Endothelium; Endothelium, Vascular - pathology; Humans; Inflammation; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - pathology; Metabolism; Nitric oxide; Nitric Oxide - metabolism; organ dysfunction; Organs; Perfusion; Protease; protease-activated receptor 2; Rats; Receptor, PAR-2 - metabolism; Serine; Time Factors; Tissues; Vasodilation
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.b17-00343

Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor activated by serine proteases released from tissues or by synthetic peptide ligands administered pharmacologically. Its wide expression in the cardiovascular system, particularly within the endothelium, vasodilation activity, and link to increased expression of inflammatory cytokines positions PAR2 as a potentially important regulator of vascular pathology under conditions of tissue inflammation, and injury; and thus, a pharmaceutical target for new therapeutics. Obesity is considered a chronic low-grade systemic inflammatory condition as inflammatory cytokines released from adipocytes are closely related to development of metabolic syndrome and related disorders. Our work over the past five-years has focused on the changes in vasomotor functions of PAR2 in metabolic syndrome, using an animal model known as the SHRSP.Z-Leprfa/IzmDmcr rats (SHRSP.ZF). In young SHRSP.ZF that had already developed impaired responses to nitric oxide, we reported that PAR2-induced endothelium-dependent vasodilation is preserved. However, this PAR2 vasodilation decreased with increasing age and further chronic exposure to the conditions of metabolism disorder. These findings raise the possibility that PAR2 regulates tissue perfusion and can protect organs from injury, which is an increasing clinical concern at later stages of metabolic syndrome. Here we present our studies on the time-dependent changes in vasoreactivity to PAR2 in metabolic syndrome and the underlying mechanisms. Furthermore, we discuss the implications of these age-related changes in PAR2 for the cardiovascular system in metabolic syndrome.